PFIZi025-A
B220c16
iPSC line
At European Collection of Authenticated Cell Cultures (ECACC)
Timepoint: 48hr post thaw
Magnification: x4
Magnification: x4
Timepoint: 48hr post thaw
Magnification: x10
Magnification: x10
Timepoint: Confluency
Magnification: x4
Magnification: x4
Timepoint: Confluency
Magnification: x10
Magnification: x10
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
| hPSCreg Name | PFIZi025-A |
| Alternative name(s) |
B220c16
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | |
Provider |
|
| Depositor | Pfizer Limited - Pfizer (PFIZ) |
| Distributors |
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)
|
External Databases |
|
| hPSCreg | PFIZi025-A |
| BioSamples | SAMEA104236756 |
| ECACC | 66540610 |
| Cellosaurus | CVCL_RG02 |
| CLO | CLO_0101700 |
| Wikidata | Q54947280 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information#
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 25-29 |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA104236757 |
hIPSC Derivation#
General |
|
| Source cell type |
peripheral blood mononuclear cellA leukocyte with a single non-segmented nucleus in the mature form found in the circulatory pool of blood.
|
| Source cell type (free text) | Erythroblast |
| Age of donor (at collection) | 25-29 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
Latest released batch |
|
| Culture medium | mTeSR™1 |
| Passage method | EDTA |
| Surface coating | Matrigel / Geltrex |
| O2 concentration | 21 |
| CO2 concentration | 5 |
| Temperature | 37 |
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| TRA 1-60 |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| SSEA-1 |
No |
Differentiation Potency
In vitro spontaneous differentiation
In vitro spontaneous differentiation
In vitro spontaneous differentiation
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Sterility |
|
| Inoculation for microbiological growth | No Contaminants Detected |
| Mycoplasma | Not Detected |
| Viability | Viable post-cryopreservation |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
18/20 (46,XX), 1/20 (45,XX,-7), 1/20 (45,XX,-12)
Passage number: 14
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|